Paper Details

  1. Home
  2. Paper Details

Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.

Author: Guico-PabiaChristine J, JiangQin, KornsteinSusan G, MusgnungJeff J, ReddySujana

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of desvenlafaxine in perimenopausal and postmenopausal women with major depressive disorder (MDD). The results show that desvenlafaxine is effective in treating MDD in this population.
Paper Details　
Original Abstract of the Article :
The risk for major depressive disorder (MDD) increases during the menopausal transition. Nonetheless, no large, placebo-controlled studies have prospectively assessed the efficacy of antidepressants in perimenopausal or postmenopausal women. This randomized, double-blind, placebo-controlled trial ev...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.4088/JCP.10m06018blu

データ提供：米国国立医学図書館（NLM）

Desvenlafaxine for Depression in Perimenopausal and Postmenopausal Women

The menopausal transition is a significant life event for women, often accompanied by a variety of physical and emotional changes. [Major depressive disorder (MDD)] is a common challenge during this period, yet limited research has explored the efficacy of antidepressants specifically in this population. This study investigated the short-term efficacy and safety of [desvenlafaxine] in perimenopausal and postmenopausal women diagnosed with MDD.

Addressing a Gap in Mental Health Research

This research fills a critical gap in understanding the treatment of MDD in perimenopausal and postmenopausal women. The study findings provide valuable insights into the efficacy and safety of desvenlafaxine in this specific population. The results have implications for clinical practice, informing treatment decisions for women experiencing depression during this phase of life.

Supporting Women's Mental Well-being

This study emphasizes the importance of addressing mental health concerns in women during the menopausal transition. It provides evidence for the efficacy of desvenlafaxine in treating MDD in this population, offering a potential treatment option for women seeking relief from depressive symptoms. It is essential for healthcare providers to be aware of these findings and to consider them when evaluating treatment options for perimenopausal and postmenopausal women with MDD.

Dr.Camel's Conclusion

Imagine a camel caravan traversing a vast desert. Just like the camels need rest and sustenance during their journey, women navigating the menopausal transition need support and care. This research helps us understand the unique needs of women during this time, offering a potential therapeutic solution for the challenges they face. It's a reminder that we should be mindful of the complexities of women's health, ensuring they receive the appropriate care and support they need.

Date :
  1. Date Completed 2010-09-09
  2. Date Revised 2015-11-19
Further Info :

Pubmed ID

20797382

DOI: Digital Object Identifier

10.4088/JCP.10m06018blu

Related Literature

Article Analysis
・Side Effects of desvenlafaxine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.